ClinicalTrials.gg

Program

P-CD19CD20-ALLO1 Cells

Its studies are mostly in Multiple Sclerosis · Lupus Erythematosus, Systemic, led by Hoffmann-La Roche.

Furthest: phase 1, since May 14, 20252 company-led studies, 1 open or runningNext primary completion: Aug 31, 2032 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche21 open or runningphase 1since May 14, 2025May 14, 2025Aug 31, 2032phase 1 · NCT07008378

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 14, 2025First studies: 2 phase 1 studiesFirst studyNCT06984341, NCT07008378

Ahead

  1. Aug 31, 2032Primary completion: phase 1 study in Multiple SclerosisNCT07008378

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07008378Multiple Sclerosis · United States1Active, not recruitingAug 31, 203260
NCT06984341Lupus Erythematosus, Systemic · United States1WithdrawnNov 1, 20330

How it is read

Names in the registry

  • “P-CD19CD20-ALLO1 Cells”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.